PCSK9 Inhibitor Landscape Shifts Again: Alnylam’s PCSK9 Inhibitor Shows Promise in Phase 1 Trial while Amgen’s Repatha Scores Another Win Jan-9-2017 by BioCoast staff On a day of big news (Amgen Wins Ban on Sanofi Sales of Praluent) in the area of PCSK9 inhibitors, Alnylam Pharmaceuticals published the results of its phase 1 trial for inclisiran Read More …
A novel vitamin D analog effectively suppresses iPTH in hemodialysis patients
A novel vitamin D analog effectively suppresses iPTH in hemodialysis patients Jan-7-2017 by BioCoast staff 2MD (DP001), a novel, oral vitamin D analog, was able to effectively reduce intact PTH (iPTH) levels in hemodialysis patients with secondary hyperparathyroidism previously treated with a vitamin D analog, with or without a calcimimetic. The results of this phase Read More …
Invokana may reduce albuminuria and renal function decline in diabetic patients
Invokana may reduce albuminuria and renal function decline in diabetic patients Jan-6-2017 by BioCoast staff Canagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT-2), (brand: Invokana, Janssen Pharmaceutica) may have renal protective effects independent of glucose control, according to a study in JASN. A secondary analysis of data from the randomized clinical trial of canagliflozin vs. glimepiride Read More …